Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes

Haller, Hermann, Ito, Sadayoshi, Izzo, Joseph L., Januszewicz, Andrzej, Katayama, Shigehiro, Menne, Jan, Mimran, Albert, Rabelink, Ton J. +4 more·2011·New England Journal of Medicine
DOI 10.1056/nejmoa1007994

Cited by (793)

Items 501–600 of 793

  1. Complete inhibition of the renin–angiotensin–aldosterone system; where do we stand?
    Shan Shan Chen, Stephen L. Seliger, Linda F. Fried · 2014 · Current Opinion in Nephrology & Hypertension
  2. Update on the ROADMAP clinical trial report: olmesartan for the prevention or delay of microalbuminuria development in Type 2 diabetes
    Christos Chatzikyrkou, Jan Menne · 2012 · Expert Review of Cardiovascular Therapy
  3. Angiotensin II receptor blocker combinations: From guidelines to clinical practice
    Krzysztof Narkiewicz · 2011 · Blood Pressure
  4. Practical efficacy of olmesartan versus azilsartan in patients with hypertension
    Yuki Kakio, Haruhito Adam Uchida, Ryoko Umebayashi, Hidemi Takeuchi, Yuka Okuyama, Yoshihisa Hanayama, Jun Wada · 2017 · Blood Pressure Monitoring
  5. Effects of anti-hypertensive treatment on major cardiovascular events in populations within prehypertensive levels: a systematic review and meta-analysis
    Zhongqiu Hong, Tao Wu, Shuxian Zhou, Boshui Huang, Jingfeng Wang, Dongmei Jin, Deng-feng Geng · 2018 · Journal of Human Hypertension
  6. Diabetische Nephropathie
    Jan Menne, Hermann G. Haller · 2011 · Der Internist
  7. Telmisartan in High Cardiovascular Risk Patients
    Roland G Asmar · 2012 · European Cardiology Review
  8. Management of Diabetes Mellitus
    Alicia Josephine Jenkins, EMMA S. SCOTT, Jordan Fulcher, Gary Kilov, Andrzej S. Januszewski · 2018 · Contemporary cardiology
  9. Clinical Trials on Diabetic Nephropathy: A Cross-Sectional Analysis
    Sergio Modafferi, Markus Ries, Vittorio Calabrese, Claus Peter Schmitt, Peter P. Nawroth, Stefan Kopf, Verena Peters · 2019 · Diabetes Therapy
  10. Early Aortic Valve Replacement versus Watchful Waiting in Asymptomatic Severe Aortic Stenosis: A Study-Level Meta-Analysis
    Michel Pompeu Sá, Luiz Rafael P. Cavalcanti, Antônio C.A. Escorel Neto, Álvaro Perazzo, Matheus Simonato, Marie-Annick A Clavel, Philippe Pîbarot, Ricardo de Carvalho Lima · 2019 · Structural Heart
  11. Are Triplicate Urine Samples Necessary to Assess Albuminuria?
    Abbas Deeb, Philippe Zaoui, Salima Le Penven, David Tartry, Pierre Lantelme, Michel Ducher, Jean‐Pierre Fauvel · 2013 · Nephron Clinical Practice
  12. Updated management of chronic kidney disease in patients with diabetes
    Virginia McCoy Hass · 2014 · JAAPA
  13. Preclinical and Clinical Effects of RAS Inhibition with a Focus on Telmisartan
    Thomas Unger · 2012 · ISRN Vascular Medicine
  14. The J-Curve Phenomenon in Hypertension
    Yuan‐Yuan Kang, Ji‐Guang Wang · 2016 · Springer eBooks
  15. Aumento de mortalidad asociado a olmesartán en pacientes diabéticos para la prevención o retraso de microalbuminuria: ¿es una causa de preocupación?
    Luciano Consuegra‐Sánchez, Juan Sanchís, Julio E. Núñez, José Domingo Cascón, Manuel Villegas, Francisco Picó · 2011 · Revista Española de Cardiología
  16. Angiotensin Receptor Blockers in Clinical Practice — Implications of the ONTARGET Study
    Sarah Jarvis · 2012 · Journal of International Medical Research
  17. Prognostic model of the adaptive changes from hypertensive cardiopathy: from mild diastolic dysfunction to depressed systolic function
    Alexis Álvarez-Aliaga, Adonis Frómeta Guerra, Alexis Suárez Quesada, David Del Llano-Sosa, Joel Berdú Saumell, Yasel Alberto Lago Santiesteban · 2020 · Medwave
  18. Microalbuminuria on admission for acute exacerbation of COPD as a predictor of all-cause mortality and future exacerbations
    Κonstantinos Bartziokas, Christos Kyriakopoulos, Evangelia C. Dounousi, Κonstantinos Κostikas · 2021 · Postgraduate Medical Journal
  19. A Review of Olmesartan-based Therapy in Targeting Effective Blood Pressure Control and Achieving Blood Pressure Goals
    MANGESH HARIHAR TIWASKAR, Ketan K Mehta, Prabhu N Kasture · 2024 · Journal of the Association of Physicians of India
  20. A thorough QTc study demonstrates that olmesartan medoxomil does not prolong the QTc interval
    Jeanne Mendell, Nobuko Matsushima, Terry E. O’Reilly, James D. Lee · 2015 · The Journal of Clinical Pharmacology
  21. Cardiorenal protection in experimental hypertension with renal failure: comparison between vasopeptidase inhibition and angiotensin receptor blockade
    Fabian Halleck, K. Schröder, Sven Holleck-Weithmann, Peter PK. Kossmehl, Reinhold Hugo Kreutz, Lars Rothermund · 2014 · Clinical and Experimental Hypertension
  22. Linear mixed‐effects model of QTc prolongation for olmesartan medoxomil
    SaeHeum Song, Nobuko Matsushima, James Lee, Jeanne Mendell · 2015 · The Journal of Clinical Pharmacology
  23. Antihypertensive Therapie bei Diabetes mellitus
    Guntram Schernthaner, Heinz Drexel, Alexander Rosenkranz, Gerit-Holger Schernthaner, Bruno Watschinger · 2016 · Wiener klinische Wochenschrift
  24. Renin Angiotensin Aldosterone System Blockers
    Shigeru Shibata, Toshiro Fujita · 2017 · Elsevier eBooks
  25. ACE-I und ARB bei chronischen Nierenerkrankungen: Was muss ich berücksichtigen?
    Martin G. Zeier · 2018 · DMW - Deutsche Medizinische Wochenschrift
  26. Diabetic nephropathy
    Vasantha Muthu Muthuppalaniappan, Michael T. Sheaff, Muhammad Magdi Yaqoob · 2015 · Medicine
  27. Real-world experience on intravitreal dexamethasone implant in patients with macular edema scheduled to undergo cataract surgery
    Chun‐Chieh Lai, Shu‐Chun Kuo · 2023 · BMC Ophthalmology
  28. Clinical trials with reno-vascular end points in patients with diabetes: Changing the scenario over the past 20 years
    Tomasz J. Block, Mark Emmanuel Cooper · 2023 · La Presse Médicale
  29. Renin Angiotensin Aldosterone System Blockers
    Shigeru Shibata, Toshiro Fujita · 2023 · Elsevier eBooks
  30. Controversies surrounding percutaneous coronary intervention in the diabetic patient
    Sara C. Martinez, David R. Holmes · 2016 · Expert Review of Cardiovascular Therapy
  31. Optimal search strategies for identifying moderators and predictors of treatment effects in PubMed
    Marcia Tummers, Ralph van Hoorn, Charlotte Levering, Andrew Booth, Gert Jan van der Wilt, Wietske Kievit · 2018 · Health Information & Libraries Journal
  32. Behandlungsziele bei Bluthochdruck und Diabetes mellitus
    Christos Chatzikyrkou, Hermann G. Haller, Jan Menne · 2012 · Der Internist
  33. The challenges of comparing results between placebo controlled randomized trials and non‐experimental new user, active comparator cohort studies: the example of olmesartan
    Wendy Camelo Castillo, Joseph A. Delaney, Til Stürmer‎ · 2014 · Pharmacoepidemiology and Drug Safety
  34. Titration of telmisartan, but not addition of amlodipine, reduces urine albumin in diabetic patients treated with telmisartan–diuretic
    Masayoshi Kojima, Masuo Ohashi, Yasuaki Dohi, Genjiro Kimura · 2012 · Journal of Hypertension
  35. The cost–effectiveness of irbesartan for hypertension
    Claudio Borghi, Riccardo Urso, Arrigo F.G. Cicero · 2015 · Expert Review of Pharmacoeconomics & Outcomes Research
  36. Urinary type IV collagen excretion predicts an increased urinary albumin-to-creatinine ratio in normoalbuminuric patients with diabetes
    Susumu Ogawa, Masato Matsushima, Masashi Okamura, Miho Senda, Takuya Sakamoto, Kazuhiro Nako, Sadayoshi Ito · 2012 · Journal of Diabetes Mellitus
  37. J-curve phenomenon: a matter of debate.
    Eirini Andrikou, Ioannis Bafakis, Charalampos A. Grassos, Anastasios Papaspyropoulos, ATHANASIOS J. KRANIDIS · 2012 · PubMed
  38. Assessment of the Cardiovascular Risk of Olmesartan Medoxomil-Based Treatment: Meta-Analysis of Individual Patient Data
    Antonia C. Wang, Ulf Stellmacher, Jennifer Schumi, Nora Tu, Paul‐Egbert Reimitz · 2016 · American Journal of Cardiovascular Drugs
  39. Medikamentöse antihypertensive Therapie
    Martin Middeke · 2015 · Der Internist
  40. Are Large Sample Size Studies the Answer to Evaluate Effects of Drug Use in Non–Clinical Trial Settings?
    Xilin Yang, Juliana C.N. Chan · 2011 · Journal of Clinical Oncology
  41. Randomized trial of an increased dose of calcium channel blocker or angiotensin II type 1 receptor blocker as an add-on intensive depressor therapy in type 2 diabetes mellitus patients with uncontrolled essential hypertension: the academie study
    ACADEMIE Study Investigators, Imaizumi, Satoshi, Shiga, Yuhei, Ogawa, Masahiro, Sako, Hideto, Nagata, Yoshihisa, Matsunaga, Akira, Shirotani, Tetsuro, Hoshino, Fumihiro, Yahiro, Eiji et al. · 2019 · Heart and Vessels
  42. Expert perspectives on incorporating glucagon-like peptide-1 receptor agonist in diabetes and chronic kidney disease: challenges and opportunities
    Jean‐Michel Halimi, Laurent Fauchier, Alexandre Karras, Chloé Amouyal, Dominique Eladari, Patrick Rossignol, Gabriel J. Choukroun, Philippe Zaoui, Nicolas Girerd, Samy Hadjadj · 2025 · European Journal of Preventive Cardiology
  43. Endostatin, soluble tumour necrosis factor receptor 1 and soluble tumour necrosis factor receptor 2 cannot predict new onset of microalbuminuria in patients with type 2 diabetes
    Florian Gunnar Scurt, Jan Menne, Sabine Brandt, Anja Bernhardt, Peter Rene Mertens, Hermann G. Haller, Christos Chatzikyrkou · 2023 · Diabetes/Metabolism Research and Reviews
  44. In Vitro Study of the Juxtaglomerular Apparatus and Its Implications in the Chronic Kidney Disease
    Sadayoshi Ito · 2015 · Hypertension
  45. Individualisierung der antihypertensiven Therapie bei Patienten mit Diabetes mellitus. Leitlinie der Österreichischen Diabetes Gesellschaft (Update 2019)
    Guntram Schernthaner, Christoph H. Saely, Gerit-Holger Schernthaner, Bruno Watschinger, Heinz Drexel · 2019 · Wiener klinische Wochenschrift
  46. Effect of renin-angiotensin-aldosterone system inhibitors on all-cause mortality and major cardiovascular events in patients with diabetes: A meta-analysis focusing on the number needed to treat and minimal clinical effect
    Xiaochun Yang, Li-Li Shao, Ying-Jun Mi, Wenhao Zhang, Nuo-Ya Liu, Ruo-Bin Liu, Xiaoxi Zhou, Weihong Zhang, Qing‐Bao Tian · 2020 · Journal of Diabetes and its Complications
  47. Use of renin–angiotensin–aldosterone system blockade in controversial chronic kidney disease populations
    Ana García‐Prieto, Úrsula Verdalles, Marián Goicoechea · 2021 · Medicina Clínica
  48. Safety and cardiovascular effectiveness of olmesartan in combination therapy for advanced hypertension: an electronic health record-based cohort study
    Ju Hyeon Kim, Hyung Joon Joo, Se Hwa Chung, Yunjin Yum, Yong Hyun Kim, Eung Ju Kim · 2023 · Journal of Hypertension
  49. Does antihypertensive treatment with renin-angiotensin system inhibitors prevent the development of diabetic kidney disease?
    Hiroki Miyazaki, Akira Babazono, Takumi Nishi, Toshiki Maeda, Takuya Imatoh, Masayoshi Ichiba, Hiroshi Une · 2015 · BMC Pharmacology and Toxicology
  50. O acometimento renal na hipertensão arterial e diabetes mellitus tipo 2: como identificar e prevenir – A visão do nefrologista
    José Mauro Vieira, José Hermógenes Rocco Suassuna · 2013 · Revista Hospital Universitário Pedro Ernesto
  51. “Withered Tree” Concept Host, Achieved by Global Contraception and Abortion, Secondary to Fragmented Germ Cells, Agonizingly Reduced Endogenous Estrogen/Androgen, Defaulted Genomic Repertoire, Deranged Cell Metabolism, Metabolic Syndrome, Result in Failure of Pharmacological Therapeutics with Advanced Technologies
    Elizabeth Jeya Vardhini Samuel, Nagarajan Natarajan, S. Ganesh Kumar · 2015 · Open Journal of Preventive Medicine
  52. Diseases of Renal Microcirculation: Diabetic Nephropathy
    Ineke J. Riphagen, Hiddo J.L. Heerspink, Rijk O. B. Gans, Sandrine Gaillard · 2014 · Springer eBooks
  53. Recent Updates on Diabetic Nephropathy
    Youn Kyung Kee, Seung Hyeok Han · 2017 · Journal of Korean Diabetes
  54. Urinary albumin-to-creatinine ratio in a first-morning void urine and prehypertension among Chinese Han women
    Jian-song Ding, Hao Yang Peng, Ying Peng, Qiu Zhang, Yanying Xu, Xiangqin Chao, Honggang Tian, Yonghong Zhang · 2011 · Blood Pressure
  55. ROADMAP and ORIENTAL Trials: The Re-emergence of J-Curve Ghost?
    Yoshiyuki Hamamoto, Hiroyuki Koshiyama · 2011 · Japanese Clinical Medicine
  56. Functional role of sodium glucose transporter in high glucose-mediated angiotensin type 1 receptor downregulation in human proximal tubule cells
    Rekha Yesudas, Russell Odell Snyder, Thomas J. Abbruscato, Thomas Thekkumkara · 2012 · American Journal of Physiology-Renal Physiology
  57. Hemmstoffe des Renin-Angiotensin-Systems
    Franz Weber, Manfred Anlauf · 2017 · Springer eBooks
  58. OBJETIVOS TERAPÉUTICOS EN HIPERTENSIÓN ARTERIAL:METAS DE PRESIÓN ARTERIAL EN LOS DIVERSOS SUBGRUPOS DE HIPERTENSOS
    Rodrigo Tagle, Mónica Acevedo B · 2018 · Revista Médica Clínica Las Condes
  59. Traitement par olmésartan et entéropathie : à propos de deux cas et revue de la littérature
    A. Sadki, Maelle le Besnerais, François Héron, Isabelle Marié · 2018 · La Revue de Médecine Interne
  60. New perspectives for the treatment of arterial hypertension: 2017 american guidelines
    Karpov IuA · 2018 · Meditsinskiy sovet = Medical Council
  61. Diabetische Nierenerkrankung (Update 2019)
    Harald Sourij, Roland Edlinger, Friedrich C. Prischl, Martin Auinger, Susanne Kaser, Sabine Horn, Bernhard Paulweber, Alexandra Kautzky‐Willer, Marcus D. Säemann, Rudolf Prager et al. · 2019 · Wiener klinische Wochenschrift
  62. Chapter 7. Hypertension complicated by other diseases
    2014 · Hypertension Research
  63. The renin–angiotensin–aldosterone system blockade in patients with advanced diabetic kidney disease
    Sheila Bermejo, Carles Oriol García, Eva Rodríguez, Clara Barrios, Sol Otero, Sergi Mojal, Julio Pascual, María José Soler · 2018 · Nefrología (English Edition)
  64. Entéropathie due à l’olmésartan
    M. Ould Sidi Mohamed, Philippe Colardelle · 2016 · Annales de Cardiologie et d Angéiologie
  65. Diabetic Chronic Kidney Disease in Type 2 Diabetes Mellitus (Albuminuric/Non-albuminuric)
    Stefanos K. Roumeliotis, Francesca Mallamaci, Carmine Zoccali · 2023 · Updates in hypertension and cardiovascular protection
  66. Entéropathie due à l’olmesartan
    M. Ould Sidi Mohamed, Philippe Colardelle · 2015 · Annales de Cardiologie et d Angéiologie
  67. Cardio-renal protection through renin–angiotensin–aldosterone system inhibition: current knowledge and new perspectives
    Stefania Paolillo, Pasquale Perrone Filardi · 2015 · European Heart Journal - Cardiovascular Pharmacotherapy
  68. Bioactive Compounds in Canola Meal
    Saira Hussain · 2015 · Charles Sturt University Research Output (CRO)
  69. Diabetic Nephropathy
    Peter R Rossing, Allan Flyvbjerg · 2024 · Wiley eBooks
  70. ACE Inhibitors and Angiotensin Receptor Blockers for the Prevention of Cardiovascular Outcomes: Recommendations from the 2024 Egyptian Cardiology Expert Consensus
    Neil R Poulter · 2025 · Cardiology and Therapy
  71. The Effect of Empagliflozin on Renal Outcomes in Patients With Established Cardiovascular Disease: Systematic Review and Meta‐Analysis of Randomised Placebo‐Controlled Trials
    Mansour Bahardoust, Fatemeh Naseri Rad, Sepideh Mousavi, Mohammadsadra Shamohammadi, Meisam Haghmoradi, Azin Ghaffari · 2026 · Endocrinology Diabetes & Metabolism
  72. Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular and non-cardiovascular outcomes in patients at high/very-high cardiovascular risk without heart failure: a systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials
    Stefano Masi, Gianluigi Savarese, Nicola Orsini, Martin H. Strauss · 2026 · European Heart Journal Open
  73. Guidelines and Straitjackets: Blood Pressure Targets in the Era of the Eighth Joint National Committee
    Kausik Umanath, Anna Marie Burgner, Julia Breyer Lewis, Jamie P. Dwyer · 2014 · American Journal of Kidney Diseases
  74. Drug Evaluation: Olmesartan Medoxomil + Rosuvastatin for the Treatment of Dyslipidemia and Concomitant Risk Factors: A Chance for Better Compliance?
    Joanna Goździkiewicz-Łapińska, Jolanta Małyszko · 2015 · Springer eBooks
  75. Aligning geriatric medicine fellowships with the Program of All-Inclusive Care for the Elderly (PACE)
    Matthew McNabney, Theodore T. Suh, Verna Reynolds Sellers, David A. Wilner · 2018 · Gerontology & Geriatrics Education
  76. Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors in Acute Myocardial Infarction Without Heart Failure
    Jihoon Kim, Danbee Kang, Hye‐Jeong Park, Taek Kyu Park, Joo Myung Lee, Jeong Hoon Yang, Young Bin Song, Jin-Ho Choi, Seung‐Hyuk Choi, Hyeon‐Cheol Gwon et al. · 2024 · The American Journal of Medicine
  77. A molecular mechanism for angiotensin II receptor blocker‐mediated slit membrane protection: Angiotensin II increases nephrin endocytosis via AT1 ‐receptor‐dependent ERK 1/2 activation
    Eva Königshausen, Ulf M. Zierhut, Martin Ruetze, Lars Christian Rump, Lorenz K. Sellin · 2024 · The FASEB Journal
  78. Benefits of antihypertensive drugs when blood pressure is below 140/90 mmHg
    Joseph L. Izzo · 2011 · Polskie Archiwum Medycyny Wewnętrznej
  79. Combination Therapy in Hypertension
    Anna Solini, José Antonio García‐Donaire, Luis Miguel Ruilope · 2012 · Current Cardiovascular Risk Reports
  80. Cardiovascular risk factor treatment targets and renal complications in high risk vascular patients: a cohort study
    the SMART study group, Sharmini Selvarajah, Yolanda van der Graaf, Frank L.J. Visseren, Michiel L. Bots · 2011 · BMC Cardiovascular Disorders
  81. Olmesartan for the Prevention or Delay of Diabetic Nephropathy: Some Considerations
    Ferrán Catalá-López, Gloria Martín-Serrano, Miguel Angel Maciá, Dolores Montero · 2012 · Revista Española de Cardiología (English Edition)
  82. Treatment of albuminuria due to diabetic nephropathy: recent trial results
    Edward J. Horwitz, Jeffrey R. Schelling · 2014 · Clinical Investigation
  83. Efficacy and safety of valsartan in reducing blood pressure and albuminuria in Chinese patients with essential hypertension: a multicenter prospective open-label observational study
    Xiaoyan Zhang, Xiaoqiang Ding, Guoliang Cao, Yueyi Deng, Xudong Xu, Hui Li, Xiaoming Zhuang · 2012 · Current Medical Research and Opinion
  84. The Long-Term Effects of RAAS Blockade on Renal Function
    César Cerezo, Luis Miguel Ruilope · 2012 · Springer eBooks
  85. A reappraisal of renin–angiotensin system blockade on microalbuminuria development
    Pantelis A. Sarafidis, George L. Bakris · 2011 · Journal of Hypertension
  86. Diabetic Retinopathy and Microalbuminuria Can Predict Macroalbuminuria and Renal Function Decline in Japanese Type 2 Diabetic Patients: Japan Diabetes Complications Study (JDCS)
    Tatsumi Moriya, Ryo Kawasaki, Hirohito Sone, Hidetoshi Yamashita, Shigehiro Katayama · 2014 · Nihon Naika Gakkai Zasshi
  87. Telmisartan: clinical evidence across the cardiovascular and renal disease continuum
    Piyush M. Patel · 2016 · Drugs & Therapy Perspectives
  88. Drei Fälle von schwerer chronischer Diarrhö mit seltener Ursache und einfacher Therapie
    K.-P. Rommel, E. Schneider, I. Witschel, U. Halm, Markus Zachäus · 2018 · Der Internist
  89. Arterial Hypertension and Cardiovascular Risk
    Renata Cífková · 2018 · Springer eBooks
  90. Effect of Percutaneous Coronary Intervention on Blood Pressure in Patients with Hypertension and coronary Heart Disease in Zagazig University Hospitals
    fouzi amsheeri, Mahmoud Shah, Tamer Mohamed Moustafa, Ahmed El-damanhory · 2019 · Zagazig University Medical Journal
  91. Geschlechtsunterschiede bei der diabetischen Nephropathie
    Ivonne Loeffler, Günter Wolf · 2020 · Der Nephrologe
  92. J-Curve Phenomenon: Does It Exist?
    Sripal Bangalore, Franz H. Messerli · 2012 · Springer eBooks
  93. Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
    M. GABRIEL KHAN · 2014 · Contemporary cardiology
  94. Hypertension and Diabetes
    W.J. Elliott · 2022 · Springer eBooks
  95. Revival of beta-blockers in arterial hypertension
    Cristiana Vitale, Ferdinando Iellamo, Maurizio Volterrani · 2012 · International Journal of Cardiology
  96. Don't blockers still have a role in hypertension?
    John Malcolm Cruickshank · 2011 · BMJ
  97. Cancer, Diabetes, and Angiotensin Blockade: A Question of Hypohydration
    Simon Nigel Thornton · 2011 · Journal of Clinical Oncology
  98. Assessing non-white ethnic participation in type 2 diabetes mellitus randomized clinical trials: A Meta-Analysis
    Rabeeyah Ahmed, Russell J. de Souza, Vincent Li, Sonia Savitri Anand · 2022 · medRxiv
  99. Diabetic Kidney Disease: State of the Art
    Christian Pérez Calvo · 2022 · Journal of Diabetes Research Review & Reports
  100. Optimizing benefits of intensive SBP control in type 2 diabetes: the crucial role of angiotensin-converting enzyme inhibitors/angiotensin-II type 2 receptor blockers
    Rui-Ting Lin, Jing‐Wei Gao, Yong-Cong Yang, Xue-Wen Chen, Zhen-Jie Gu, Lei-Gang Tian, Zhe-Lin Chen, Lingyu Zhang · 2025 · Journal of Hypertension